期刊文献+

HPLC法测定盐酸度洛西汀肠溶胶囊有关物质

Determination of Related Substances in Duloxetine Hydrochloride Enteric-coated Capsules by HPLC
下载PDF
导出
摘要 建立了盐酸度洛西汀有关物质测定的高效液相色谱(HPLC)方法。采用ZorbaxSB-C8柱(4.6 mm×75 mm,3.5μm),以磷酸盐缓冲液-甲醇-四氢呋喃(体积比为587∶323∶90)为流动相,在检测波长为230 nm的条件下:主药和有关物质能较好地分离,在38.8~155.2μg/mL(r=1.000 0,n=8)内,度洛西汀质量浓度与峰面积线性关系良好;分别在0.08~0.33μg/mL(r=0.999 9,n=8)和0.08~0.32μg/mL(r=0.999 7,n=8)内,杂质Ⅲ和Ⅷ的质量浓度与峰面积呈良好的线性关系。该方法简便、准确、可行、精密度高,可用于盐酸度洛西汀肠溶胶囊有关物质的质量控制。 The paper established a method for the determination of duloxetine and related substances in duloxetine hydrochloride enteric-coated capsule by high performance liquid chromatography(HPLC).The test was performed in a ZorbaxSB-C8column(4.6mm×75mm,3.5μm)with phosphate buffer-methanol-tetrahydrofuran(the volume ratio was587︰323︰90)as a mobile phase at the detected UV wavelength of230nm.The resolution between duloxetine hydrochloride and the other peaks met the requirements.The standard curves of duloxetine hydrochloride and the related substanceⅢandⅧshowed a good linearity in the range of38.8-155.2g/mL,0.08-0.33g/mL and0.08-0.32g/mL,respectively.This method is simple,accurate,feasible and higher precise,it can be used for the quality control of the related impurities in duloxetine hydrochloride enteric-coated capsule.
作者 徐豪 丁云晖 张英 邱明丰 XU Hao;DING Yunhui;ZHANG Ying;QIU Mingfeng
出处 《上海化工》 CAS 2018年第12期42-45,共4页 Shanghai Chemical Industry
关键词 盐酸度洛西汀肠溶胶囊 HPLC 检测 Duloxetine hydrochloride HPLC Determination
  • 相关文献

参考文献1

二级参考文献16

  • 1Thor KB,Kirby M,Viktrup L.Serotonin and noradrenaline involvement in urinary incontinence,depression and pain:scientific basis for overlapping clinical efficacy from a single drug,duloxetine[J].Int J Clin Pract,2007,61(8):1349-1355.
  • 2Detke MJ,Lu Y,Goldstein DJ,et al.Duloxetine 60mg once daily dosing versus placebo in the acute treatment of major depression[J].J Psychiatr Res,2002,36(6):383-390.
  • 3Detke MJ,Lu Y,Goldstein DJ,et al.Duloxetine,60mg once daily for major depressive disorder:a randomized double-blind placebo-controlled trial[J].J Clin Psychiatry,2002,63 (4):308-315.
  • 4Lee P,Shu L,Xu X,et al.Once -daily duloxedne 60mg in the treatment of major depressive disorder:multicenter,double-blind,randomized,paroxetine-controlled,non-inferiority trial in China,Korea,Taiwan and Brazil[J].Psychiatry Clin Neurosci,2007,61(3):295-307.
  • 5Brannan SK,Mallinckrodt CH,Brown EB,et al.Duloxetine 60mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder[J].J Psychiatr Res,2005,39 (1):43-53.
  • 6Jain R.Single-action versus dual-action antidepressants[J].J.Clin Psychiatry,2004,6 (suppl 1):7-11.
  • 7Perahia DG,Gilaberte I,Wang F,et al.Duloxetine in the prevention of relapse of major depressive disorder:double-blind placebo-controlled study[J].Br J Psychiatry,2006,188(4):346-353.
  • 8Allugander C,Hartford J,Russell J,et al.Pharmacotherapy of generalized anxiety disorder:results of duloxetine treatment from a pooled analysis of three clinical trials[J].Curr Med Res Opin,2007,23(6); 1245-1252.
  • 9Davidson J,Wittchen H,Llorca P,et al.Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder:a double-blind placebo-controlled trial[J].Eur Neuropsychopharmacol,2008,18(9):673-681.
  • 10Zinner N,Dmochowski R,Miklos J,et al.Duloxetine versus placebo in the treatment of stress urinary incontinence (SUI)[J].Neurourol Urodyn,2002,21(4):383-384.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部